Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study
Cutaneous manifestation is a common presentation of LCH and is usually a leading clue for the disease diagnosis. Having cutaneous lesions did not show a significantly early age onset at diagnosis compared to those without skin lesions, P value = 0.71. In the present study, cutaneous findings were found as 77.7%. Seborrheic dermatitis-like lesions were the most common cutaneous type (42.8%), followed by papules/nodules/masses (28.5%), petechiae/hemorrhagic lesions (17.8%), and eczematous lesions (10.7%). Time to diagnosis of LCH presented with seborrheic dermatitis-like lesions was significantly longer than other cutaneous presentations, P value = 0.0011.
What is Known?
• Cutaneous manifestation is a common presentation of LCH and is usually a leading clue for the disease diagnosis.
What is New?
• Patients with LCH who have the manifestations of seborrheic dermatitis-like lesions can have a delayed diagnosis due to the difficulty in distinguishing normal from seborrheic dermatitis lesions.
• Petechiae/hemorrhagic cutaneous signs in addition to the normal seborrheic dermatitis are the clue to the early disease detection.
KeywordsLangerhans cell histiocytosis LCH Seborrheic dermatitis Petechiae Hemorrhagic lesions
Langerhans cell histiocytosis
- S-S LCH
Single-system Langerhans cell histiocytosis
- M-S LCH
Multisystem Langerhans cell histiocytosis
We would like to acknowledge Prof. James Arthur Will, for editing the manuscript via publication clinic KKU, Thailand.
L. Techasatian contributed to the conception and design of the study, data analysis, interpretation of findings, drafting the article, revising the article, and final approval of the version submitted. S. Poompuen contributed to study conception and data collection. J. Chaiyarit contributed to data processing and data analysis, critical revision of the article, and final approval of the version submitted.
Compliance with ethical standards
Ethical approval and informed consent
The study was approved by the institutional review board of Faculty of Medicine, Khon Kaen University, Thailand (IRB no. #HE591399), before enrolling any participants.
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Wollina U, Langner D, Hansel G, Schönlebe J (2016) Cutaneous Langerhans cell histiocytosis: the spectrum of a rare cutaneous neoplasia. Wien Med Wochenschr 1946:5Google Scholar
- 4.Ng SS-Y, Koh MJ-A, Tay Y-K (2013) Cutaneous Langerhans cell histiocytosis: study of Asian children shows good overall prognosis. Acta Paediatr Oslo Nor 1992 102(11):e514–e518Google Scholar
- 7.Flores-Terry MA, Sanz-Trenado JL, García-Arpa M, Cortina-de la Calle MP (2018) Cutaneous Langerhans cell histiocytosis presenting in adulthood. Actas DermosifiliogrGoogle Scholar
- 10.Chong VC-L, Tan CL, Chee Y-L, De Mel S (2018) A young patient with a lytic skull lesion. J Clin Pathol 26Google Scholar
- 11.Zhu H, Ma Y, Sun L, Zhang R, Lv L, Wang A (2018) Langerhans cell histiocytosis with lymph node involvment presenting as erythroderma. Acta Derm VenereolGoogle Scholar
- 15.Ahuja A, Uppe A, Nair G (2018) Multisystem involvement of Langerhans cell histiocytosis. J Assoc Physicians India 66(4):75–76Google Scholar
- 16.Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M et al (1997) Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 29(3):157–166CrossRefGoogle Scholar
- 19.Bellinato F, Maurelli M, Colato C, Balter R, Girolomoni G, Schena D (2018) BRAF V600E expression in juvenile xanthogranuloma occurring after Langerhans cell histiocytosis. Br J DermatolGoogle Scholar